CHRS (Coherus BioSciences) Net earnings per share growth this year

Coherus Biosciences (CHRS) is currently shifting its strategic direction, pivoting from biosimilars toward the development of its own immuno-oncology pipeline and cost optimization. A key advantage is its monopoly in treating rare carcinomas, despite pricing battles in other segments. However, logistical disruptions and sanctions are limiting expansion. The annual change in earnings per share reflects the pace of the business turnaround, where 43.10 expresses the current value of the metric.
Financial and market metric breakdowns for coherus.com (CHRS)

Coherus Biosciences (CHRS) specializes in developing affordable biosimilars and introducing the innovative drug Loqtorzi into the oncology segment. By analyzing the EPS YoY percentage shift, an investor assesses the rate of change in net income per share relative to the previous year, which allows for determining the effectiveness of the business model's adaptation to the cost of borrowed capital and the company's overall profitability resilience.